MedPath

UZ Leuven

UZ Leuven logo
🇧🇪Belgium
Ownership
Private
Established
1971-01-01
Employees
5K
Market Cap
-
Website
https://www.uzleuven.be/nl

Clinical Trials

24

Active:5
Completed:0

Trial Phases

4 Phases

Phase 1:4
Phase 2:1
Phase 3:2
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials

Phase 4
13 (54.2%)
Phase 1
4 (16.7%)
3 (12.5%)
Phase 3
2 (8.3%)
phase_1_2
1 (4.2%)
Phase 2
1 (4.2%)
No trials found

News

eXmoor Pharma and KU Leuven Form Strategic Alliance to Accelerate AAV Gene Therapy Development

eXmoor Pharma and KU Leuven have established a strategic partnership to support a new cell and gene therapy hub, focusing on accelerating AAV gene therapies from bench to first-in-human trials.

Hybrid Closed-Loop Systems Show Significant Glycemic Benefits for Pregnant Women with Type 1 Diabetes

Two major clinical trials demonstrate that hybrid closed-loop insulin delivery systems significantly improve time in range and reduce hypoglycemia in pregnant women with type 1 diabetes compared to standard care.

KU Leuven and UZ Leuven Launch €14 Million Advanced Therapy Production Facility

KU Leuven and UZ Leuven are investing €14 million to establish an Advanced Therapy Medicinal Products (ATMP) facility on the Gasthuisberg campus, scheduled to be operational by late 2025.

© Copyright 2025. All Rights Reserved by MedPath